Results 81 to 90 of about 22,517 (214)

Octreotide treatment of patients with hepatocellular carcinoma - a retrospective single centre controlled study

Journal of Experimental & Clinical Cancer Research, 2009
Background Studies of treatment with octreotide of patients with hepatocellular carcinoma (HCC) gave conflicting results. We analyzed retrospectively the survival of our patients treated with octreotide monotherapy and compared it to stage-matched ...
Müller Christian, Peck-Radosavljevic Markus, Kettenbach Joachim, Schöniger-Hekele Maximilian   +3 more
doaj   +1 more source

Octreotide s.c. depot provides sustained octreotide bioavailability and similar IGF-1 suppression to octreotide LAR in healthy volunteers

British Journal of Clinical Pharmacology, 2015
Aims The aim was to assess the pharmacokinetics, pharmacodynamics, safety and tolerability of octreotide subcutaneous (s.c.) depot, a novel octreotide formulation. Methods This was a phase I, randomized, open label study.
F. Tiberg, John Roberts, C. Cervin, M. Johnsson, S. Sarp, A. Tripathi, Margareta Linden   +6 more
semanticscholar   +1 more source

Multicenter Study on the Clinical Characteristics, Diagnosis, and Treatment Outcomes of Insulinoma: Insights From 15 Medical Centres

Clinical Endocrinology, Volume 103, Issue 1, Page 57-65, July 2025.
ABSTRACT Objective This study aimed to evaluate the clinical characteristics, diagnostic approaches, and treatment outcomes of insulinoma patients from diverse regions across the country. We conducted a retrospective analysis of medical records from 76 adult patients diagnosed with insulinoma between 2018 and 2023 at 15 medical centres.
Şenay Topsakal, Güzin Fidan Yaylalı, Zeliha Yarar, Fatma Avcı Merdin, Seda Karslı, Sema Çiftçi, Mehmet Sercan Ertürk, Barış Önder Pamuk, Ayşe Özdemir Yavuz, Kader Uğur, Ogün Bilen, Sayid Shafi Zuhur, İsmail Engin, Mehmet Güven, Fazıl Mustafa Cesur, Sevgül Fakı, Şefika Burçak Polat, Bekir Çakır, Hatice Özışık, Gökçen Ünal Kocabaş, Mehmet Erdoğan, Şevki Çetinkalp, İlkcan Çerçi Koçar, Esen Akbay, Sema Yarman   +24 more
wiley   +1 more source

Octreotide acetate enhanced radio sensitivity and induced apoptosis in MCF7 breast cancer cell line

Journal of Radiation Research and Applied Sciences, 2022
Introduction: Breast cancer is the most common type of cancer among women. Radiotherapy is one of the treatment options for breast cancer; it plays a significant role in tumour control after surgery. However, radio resistance developed by tumour cells is
Alkhansa Salih Mahmoud, Md Zuki Abu Bakar, Hazilawati Hamzah, Tengku Ahbrizal Tengkue Ahmad, Mohd Hezmee Mohd Noor   +4 more
doaj  

Octreotide in the management of recurrent gastrointestinal bleed in patients supported by continuous flow left ventricular assist devices.

ASAIO journal (1992), 2015
Gastrointestinal (GI) bleeding is the most common cause of readmission in patients supported by continuous flow left ventricular assist devices (CF-LVAD).
Renzo Y Loyaga-Rendon, Taimoor Hashim, J. Tallaj, D. Acharya, W. Holman, J. Kirklin, S. Pamboukian   +6 more
semanticscholar   +1 more source

Octreotide (somatostatin analog) attenuates cardiac ischemia/reperfusion injury via activating nuclear factor (erythroid-derived 2)-like 2 (Nrf2) signaling pathway in rat model of hyperthyroidism

Future Journal of Pharmaceutical Sciences, 2020
Background Hyperthyroidism is known to increase the risk of ischemic heart diseases. Octreotide has been reported to attenuate ischemia/reperfusion (I/R) injury.
Randa Salah Gomaa, Nevertyty Mohamed Mahmoud, Nourelhuda Abdelaziz Mohammed   +2 more
doaj   +1 more source

The use of octreotide in the treatment of chylothorax following cardiothoracic surgery.

Interactive Cardiovascular and Thoracic Surgery, 2015
A best evidence topic in cardiothoracic surgery was written according to a structured protocol. The question addressed was 'Is octreotide (a long-acting somatostatin analogue) effective in patients with post-operative or traumatic chylothorax as a part ...
N. Ismail, Jacqueline Gordon, J. Dunning
semanticscholar   +1 more source

Association of dose escalation of octreotide long-acting release on clinical symptoms and tumor markers and response among patients with neuroendocrine tumors

Cancer Medicine, 2015
Patients with nonresectable metastatic neuroendocrine tumors (NETs) experience symptoms of hormone hypersecretion including diarrhea, flushing, and bronchoconstriction, which can interfere with quality of life [Anthony and Vinik (2011) Pancreas, 40:987].
Khalid Al-Efraij, Mohammed A. Aljama, H. Kennecke   +2 more
semanticscholar   +1 more source

Use of Octreotide for the Management of Chyle Fistula Following Neck Dissection.

JAMA Otolaryngology - Head and Neck Surgery, 2015
IMPORTANCE Chyle fistula is an uncommon complication of neck surgery. A variety of management strategies have been described, including diet restriction, parenteral nutrition, use of pressure dressings, and revision surgery. Octreotide has been used with
Mark S. Swanson, Rachael Hudson, Nipun Bhandari, U. Sinha, D. Maceri, N. Kokot   +5 more
semanticscholar   +1 more source

A case of antibody formation against octreotide visualized with ¹¹¹In‐octreotide scintigraphy

Clinical Endocrinology, 1993
SummaryA case of antibody formation in a patient with carcinoid syndrome is described. The patient was treated with octreotide in dosages up to 1 5 mg/day. Serum samples were analysed for the presence of octreotide antibodies before and after 20 months of octreotide treatment.
S. W. J. Lamberts, Dik J. Kwekkeboom, E.P. Krenning, Leo J. Hofland, J Assies, Jean Claude Reubi   +5 more
openaire   +3 more sources